This page is intended to provide access to NervGen Pharma Corp. (NGEN) regulatory filings and related disclosures, alongside AI-generated summaries that help explain their contents in clear language. While no SEC filings are listed in the current data, NervGen’s public statements outline the clinical and regulatory context in which future filings would be prepared.
NervGen describes itself as a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. Its lead candidate, NVG-291, is a subcutaneously administered neuroreparative peptide evaluated in the Phase 1b/2a CONNECT SCI Study in individuals with chronic SCI, with ongoing enrollment in subacute SCI and preparation for a Phase 3 trial in chronic SCI.
According to the company, NVG-291 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of spinal cord injury. NervGen also references regulatory meetings with the FDA, including a Type C meeting and a planned End-of-Phase 2 meeting to align on the development and registration pathway for NVG-291.
As SEC filings such as annual reports (Form 10-K), quarterly reports (Form 10-Q) or current reports (Form 8-K) become available, this page can surface them with AI-powered highlights of key sections, such as clinical development updates for NVG-291 and NVG-300, risk factor discussions related to neuroreparative drug development, and disclosures around regulatory designations and trial status. AI summaries can assist readers in navigating lengthy documents by pointing to passages that discuss NervGen’s spinal cord injury focus, neurotraumatic and neurologic indications, and the company’s stated mission to enable nervous system repair.
NervGen Pharma Corp. (NGEN) amended and restated its unaudited results for the three and six months ended June 30, 2026 and 2025 after identifying non-cash valuation errors in stock options and certain warrant liabilities, plus a reclassification of share issuance costs. The company said the adjustments did not affect cash, cash flow or liquidity, and its audit committee concluded the earlier statements for the affected periods should no longer be relied upon.
For the six months ended June 30, 2026, NervGen reported net income of C$8,877,392, compared with a restated net loss of C$13,004,306 a year earlier. The 2026 result included a C$29,451,917 unrealized gain from remeasuring warrant derivatives; diluted loss per share was C$0.22, versus a C$0.18 loss per share in 2025. Research and development expense was C$12,575,990, and operating cash use was C$13,932,238.
As of June 30, 2026, cash and cash equivalents were C$86,789,698. The material weaknesses involved undocumented valuation inputs and preparation and review of complex accounting concentrated among a small finance team. The company says remediation requires effective controls to operate for a sufficient period and testing to confirm effectiveness.
NERVGEN Pharma Corp. amended and restated its annual financial statements and management’s discussion and analysis for fiscal years 2025 and 2024 after identifying non-cash valuation errors in its accounting for stock options and certain outstanding derivative warrant liabilities. The adjustments reduce previously reported stock-based compensation expense and warrant liabilities, with corresponding adjustments to unrealized gains and losses on warrant derivatives. The company says the corrections do not affect its cash position, cash flow or liquidity; the original statements and MD&A should no longer be relied upon.
The audit committee of NERVGEN PHARMA CORP. concluded on September 25, 2026, that the company’s audited financial statements for the years ended December 31, 2025 and 2024, and unaudited interim financial information for the quarter ended June 30, 2026, should no longer be relied upon. NERVGEN intends to restate the annual statements through an amendment to its Form 40-F for the year ended December 31, 2025, and the interim information through an amendment to its Form 6-K.
The corrections address non-cash valuation errors in accounting for stock options and certain outstanding derivative warrant liabilities. They reduce previously reported stock-based compensation expense and warrant liabilities, with corresponding adjustments to unrealized gains and losses on warrant derivatives. NERVGEN said the changes do not affect its cash position, cash flow or liquidity; management and the audit committee are evaluating and finalizing the accounting conclusions and restatement adjustments.
NERVGEN Pharma Corp. (NGEN) gave notice of a change of auditor dated September 15, 2026. KPMG LLP (Canada) agreed with the notice. KPMG LLP (US) agreed with statements 2 and 3 pertaining to it, but said it was not in a position to agree or disagree with statements 1, 4 and 5, or the parts of statement 3 that did not pertain to it.
NervGen Pharma Corp. reports interim results for the three and six months ended June 30, 2026, as a clinical-stage, pre-revenue biotech focused on neuroreparative therapeutics, led by NVG-291 for chronic tetraplegia, with plans for a Phase 3 trial.
Total assets rose to $90.2 million at June 30, 2026 from $23.2 million at year-end 2025, driven mainly by a May 2026 underwritten public offering of 24.0 million units for gross proceeds of $82.9 million. Cash and cash equivalents increased to $86.8 million, and management believes existing working capital is sufficient for the ensuing 12 months.
For Q2 2026, research and development expenses were $7.9 million and general and administrative expenses were $4.3 million, reflecting higher CMC, clinical start-up and Nasdaq-related costs. The quarter’s net loss was $29.2 million, including a $19.4 million non-cash unrealized loss on U.S. dollar–denominated warrant derivatives, which increased the related liability to $68.6 million. The accumulated deficit reached $177.7 million, and the company continues to depend on external financing and potential non-dilutive funding to advance development.
NervGen Pharma Corp. has entered into a Sales Agreement with Leerink Partners LLC that allows the company to issue and sell up to US$50,000,000 of its common shares from time to time. These sales will be made as an at-the-market offering on Nasdaq or other U.S. trading venues, at prevailing market prices.
The shares are offered under NervGen’s existing Form F-10 shelf registration, which covers up to US$250,000,000 of various securities, and a corresponding Canadian short form base shelf prospectus. NervGen controls when and how many shares are sold via Placement Notices, can suspend or terminate offerings at any time, and is not obligated to sell any shares.
Leerink acts as selling agent on a commercially reasonable efforts basis, with cash settlement of net proceeds to NervGen on each trading day that shares are sold. The company agrees to use net proceeds as described in the “Use of Proceeds” sections of its U.S. and Canadian prospectuses.
NervGen Pharma Corp. completed an underwritten public Offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares at a combined public offering price of US$2.50 per share and warrant. This equity financing is expected to generate approximately US$60.0 million in gross proceeds before fees and expenses, excluding any cash that may come from future warrant exercises.
Each warrant carries an exercise price of US$3.68 per share, is immediately exercisable, and expires five years from issuance. NervGen plans to use the net proceeds, together with existing cash, to advance its NVG-291 program through clinical studies and for general corporate and working capital needs. Insider PFP Biosciences Holdings LLC participated in the Offering, increasing its holdings to 15,488,673 common shares (14.58% of outstanding) and 8,144,335 warrants, which include a 19.99% ownership cap on warrant exercise.
NervGen Pharma reports new independent, blinded biomechanical gait analyses from its Phase 1b/2a CONNECT SCI study showing a statistically significant treatment effect of NVG-291 versus placebo on a multivariate measure of gait quality in people with chronic tetraplegia.
The analyses, performed by AI movement specialist Newton Tech and independently verified by a computational biomedicine department, assessed coordination, mechanical effort and postural stability, which are described as hallmarks of genuine neural recovery rather than compensation. Participants were 1–10 years post–spinal cord injury, with a mean of 3.5 years.
NervGen states these results extend previously reported clinical improvements and support advancing NVG-291 into the Phase 3 RESTORE registrational study in chronic tetraplegia, which is planned to start in mid-2026 following an earlier End-of-Phase 2 FDA meeting and ongoing regulatory dialogue.
NervGen Pharma Corp. amended its amended and restated short form base shelf prospectus to increase the aggregate offering capacity from U.S.$150,000,000 to U.S.$250,000,000, permitting offers of Common Shares, Debt Securities, Subscription Receipts, Warrants and Units to be made from time to time during the 25-month shelf period. The prospectus states the securities may be offered by the Company or by selling securityholders, and that specific terms will be set forth in prospectus supplements. The prospectus also discloses corporate, clinical and financial context including recent Phase 1b/2a data for NVG-291, the Private Placement of 4,785,674 units for aggregate gross proceeds of U.S.$10,049,915, and cash and loss figures for the period ended September 30, 2025.